Univariate and multivariate analysis for complete remission (evaluable patients)
Prognostic factor . | Univariate . | Multivariate . | ||
---|---|---|---|---|
P-value . | N . | Odd ratio . | P-value . | |
Age (y)5-150 | .4434 | |||
< 45 | ||||
> 45 | ||||
Baseline WBC (cells/μL)5-150 | .6215 | |||
< 5 000 | ||||
> 5 000 | ||||
Sex | .6799 | |||
Female | ||||
Male | ||||
Relapse status group | .00003 | 56 | 0.014 | .0015 |
Newly diagnosed | ||||
Relapse (Group 1) | ||||
Relapse (Group 2) | ||||
Prior oral ATRA | .0027 | |||
No | ||||
Yes | ||||
Prior ATRA syndrome | .1123 | |||
No | ||||
Yes | ||||
Current ATRA syndrome | .3420 | |||
No | ||||
Yes | ||||
Baseline performance status | .9083 | |||
Intubation | .019 | 56 | 0.249 | .0002 |
No | ||||
Yes | ||||
DIC | .3243 | |||
No | ||||
Yes |
Prognostic factor . | Univariate . | Multivariate . | ||
---|---|---|---|---|
P-value . | N . | Odd ratio . | P-value . | |
Age (y)5-150 | .4434 | |||
< 45 | ||||
> 45 | ||||
Baseline WBC (cells/μL)5-150 | .6215 | |||
< 5 000 | ||||
> 5 000 | ||||
Sex | .6799 | |||
Female | ||||
Male | ||||
Relapse status group | .00003 | 56 | 0.014 | .0015 |
Newly diagnosed | ||||
Relapse (Group 1) | ||||
Relapse (Group 2) | ||||
Prior oral ATRA | .0027 | |||
No | ||||
Yes | ||||
Prior ATRA syndrome | .1123 | |||
No | ||||
Yes | ||||
Current ATRA syndrome | .3420 | |||
No | ||||
Yes | ||||
Baseline performance status | .9083 | |||
Intubation | .019 | 56 | 0.249 | .0002 |
No | ||||
Yes | ||||
DIC | .3243 | |||
No | ||||
Yes |
ATRA = all-trans retinoic acid; WBC = white blood cell count; DIC = disseminated intravascular coagulation.
Age as a continuous parameter P = .4434; WBC as a continuous parameter P = .6215.